Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis

OBJECTIVES: To determine s.c. tocilizumab (s.c.-TCZ) dosing regimens for systemic JIA (sJIA) and polyarticular JIA (pJIA). METHODS: In two 52-week phase 1 b trials, s.c.-TCZ (162 mg/dose) was administered to sJIA patients every week or every 2 weeks (every 10 days before interim analysis) and to pJI...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruperto, Nicolino, Brunner, Hermine I, Ramanan, Athimalaipet V, Horneff, Gerd, Cuttica, Rubén, Henrickson, Michael, Anton, Jordi, Boteanu, Alina Lucica, Penades, Inmaculada Calvo, Minden, Kirsten, Schmeling, Heinrike, Hufnagel, Markus, Weiss, Jennifer E, Pardeo, Manuela, Nanda, Kabita, Roth, Johannes, Rubio-Pérez, Nadina , Hsu, Joy C, Wimalasundera, Sunethra, Wells, Chris, Bharucha, Kamal , Douglass, Wendy, Bao, Min, Mallalieu, Navita L, Martini, Alberto, Lovell, Daniel, Benedetti, Fabrizio De
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487273/
https://www.ncbi.nlm.nih.gov/pubmed/33506875
http://dx.doi.org/10.1093/rheumatology/keab047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487273/
https://www.ncbi.nlm.nih.gov/pubmed/33506875
http://dx.doi.org/10.1093/rheumatology/keab047

Ejemplares similares